TY - JOUR
T1 - Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer - Association With Patient and Disease Characteristics and Effect on Prognosis
AU - Fasching, Peter A.
AU - Yadav, Siddhartha
AU - Hu, Chunling
AU - Wunderle, Marius
AU - Häberle, Lothar
AU - Hart, Steven N.
AU - Rübner, Matthias
AU - Polley, Eric C.
AU - Lee, Kun Y.
AU - Gnanaolivu, Rohan D.
AU - Hadji, Peyman
AU - Hübner, Hanna
AU - Tesch, Hans
AU - Ettl, Johannes
AU - Overkamp, Friedrich
AU - Lux, Michael P.
AU - Ekici, Arif B.
AU - Volz, Bernhard
AU - Uhrig, Sabrina
AU - Lüftner, Diana
AU - Wallwiener, Markus
AU - Müller, Volkmar
AU - Belleville, Erik
AU - Untch, Michael
AU - Kolberg, Hans Christian
AU - Beckmann, Matthias W.
AU - Reis, André
AU - Hartmann, Arndt
AU - Janni, Wolfgang
AU - Wimberger, Pauline
AU - Taran, Florin Andrei
AU - Fehm, Tanja N.
AU - Wallwiener, Diethelm
AU - Brucker, Sara Y.
AU - Schneeweiss, Andreas
AU - Hartkopf, Andreas D.
AU - Couch, Fergus J.
N1 - Publisher Copyright:
© American Society of Clinical Oncology.
PY - 2021/5/20
Y1 - 2021/5/20
N2 - PURPOSEAmong patients with metastatic breast cancer (mBC), the frequency of germline mutations in cancer susceptibility genes and the clinical relevance of these mutations are unclear. In this study, a prospective cohort of patients with mBC was used to determine mutation rates for breast cancer (BC) predisposition genes, to evaluate the clinical characteristics of patients with mutations, and to assess the influence of mutations on patient outcome.PATIENTS AND METHODSGermline DNA from 2,595 patients with mBC enrolled in the prospective PRAEGNANT registry was evaluated for mutations in cancer predisposition genes. The frequencies of mutations in known BC predisposition genes were compared with results from a prospective registry of patients with nonmetastatic BC sequenced using the same QIAseq method and with public reference controls. Associations between mutation status and tumor characteristics, progression-free survival, and overall survival were assessed.RESULTSGermline mutations in 12 established BC predisposition genes (including BRCA1 and BRCA2) were detected in 271 (10.4%) patients. A mutation in BRCA1 or BRCA2 was seen in 129 patients (5.0%). BRCA1 mutation carriers had a higher proportion of brain metastasis (27.1%) compared with nonmutation carriers (12.8%). Mutations were significantly enriched in PRAEGNANT patients with mBC compared with patients with nonmetastatic BC (10.4% v 6.6%, P <.01). Mutations did not significantly modify progression-free survival or overall survival for patients with mBC.CONCLUSIONMultigene panel testing may be considered in all patients with mBC because of the high frequency of germline mutations in BRCA1/2 and other BC predisposition genes. Although the prognosis of mutation carriers and nonmutation carriers with mBC was similar, differences observed in tumor characteristics have implications for treatment and for future studies of targeted therapies.
AB - PURPOSEAmong patients with metastatic breast cancer (mBC), the frequency of germline mutations in cancer susceptibility genes and the clinical relevance of these mutations are unclear. In this study, a prospective cohort of patients with mBC was used to determine mutation rates for breast cancer (BC) predisposition genes, to evaluate the clinical characteristics of patients with mutations, and to assess the influence of mutations on patient outcome.PATIENTS AND METHODSGermline DNA from 2,595 patients with mBC enrolled in the prospective PRAEGNANT registry was evaluated for mutations in cancer predisposition genes. The frequencies of mutations in known BC predisposition genes were compared with results from a prospective registry of patients with nonmetastatic BC sequenced using the same QIAseq method and with public reference controls. Associations between mutation status and tumor characteristics, progression-free survival, and overall survival were assessed.RESULTSGermline mutations in 12 established BC predisposition genes (including BRCA1 and BRCA2) were detected in 271 (10.4%) patients. A mutation in BRCA1 or BRCA2 was seen in 129 patients (5.0%). BRCA1 mutation carriers had a higher proportion of brain metastasis (27.1%) compared with nonmutation carriers (12.8%). Mutations were significantly enriched in PRAEGNANT patients with mBC compared with patients with nonmetastatic BC (10.4% v 6.6%, P <.01). Mutations did not significantly modify progression-free survival or overall survival for patients with mBC.CONCLUSIONMultigene panel testing may be considered in all patients with mBC because of the high frequency of germline mutations in BRCA1/2 and other BC predisposition genes. Although the prognosis of mutation carriers and nonmutation carriers with mBC was similar, differences observed in tumor characteristics have implications for treatment and for future studies of targeted therapies.
UR - http://www.scopus.com/inward/record.url?scp=85106552173&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106552173&partnerID=8YFLogxK
U2 - 10.1200/JCO.20.01200
DO - 10.1200/JCO.20.01200
M3 - Article
C2 - 33780288
AN - SCOPUS:85106552173
SN - 0732-183X
VL - 39
SP - 1619
EP - 1630
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 15
ER -